Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 8
2004 8
2005 10
2006 9
2007 3
2008 9
2009 4
2010 8
2011 2
2012 1
2013 6
2014 8
2015 9
2016 3
2017 6
2018 8
2019 6
2020 6
2021 9
2022 8
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group. Shapiro J, et al. Among authors: van lanschot jjb. Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5. Lancet Oncol. 2015. PMID: 26254683 Clinical Trial.
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van der Sangen MJC, Rozema T, Ten Kate FJW, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS Study Group. Eyck BM, et al. Among authors: van lanschot jjb. J Clin Oncol. 2021 Jun 20;39(18):1995-2004. doi: 10.1200/JCO.20.03614. Epub 2021 Apr 23. J Clin Oncol. 2021. PMID: 33891478 Clinical Trial.
International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG).
Low DE, Alderson D, Cecconello I, Chang AC, Darling GE, DʼJourno XB, Griffin SM, Hölscher AH, Hofstetter WL, Jobe BA, Kitagawa Y, Kucharczuk JC, Law SY, Lerut TE, Maynard N, Pera M, Peters JH, Pramesh CS, Reynolds JV, Smithers BM, van Lanschot JJ. Low DE, et al. Among authors: van lanschot jj. Ann Surg. 2015 Aug;262(2):286-94. doi: 10.1097/SLA.0000000000001098. Ann Surg. 2015. PMID: 25607756
Hereditary Factors in Esophageal Adenocarcinoma.
van Nistelrooij AM, Dinjens WN, Wagner A, Spaander MC, van Lanschot JJ, Wijnhoven BP. van Nistelrooij AM, et al. Among authors: van lanschot jj. Gastrointest Tumors. 2014 Jun;1(2):93-8. doi: 10.1159/000362575. Epub 2014 May 9. Gastrointest Tumors. 2014. PMID: 26675496 Free PMC article. Review.
Reply to B. Li et al.
Eyck BM, Wijnhoven BPL, van Lanschot JJB. Eyck BM, et al. Among authors: van lanschot jjb. J Clin Oncol. 2021 Oct 1;39(28):3190-3191. doi: 10.1200/JCO.21.01543. Epub 2021 Aug 2. J Clin Oncol. 2021. PMID: 34339303 No abstract available.
Cyclooxygenase-2 and gastric carcinogenesis.
Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, Haglund C, Van Lanschot JJ, Offerhaus GJ, Ristimaki A. Saukkonen K, et al. Among authors: van lanschot jj. APMIS. 2003 Oct;111(10):915-25. doi: 10.1034/j.1600-0463.2003.1111001.x. APMIS. 2003. PMID: 14616542 Review.
The optimal neoadjuvant treatment of locally advanced esophageal cancer.
van der Wilk BJ, Eyck BM, Lagarde SM, van der Gaast A, Nuyttens JJME, Wijnhoven BPL, van Lanschot JJB. van der Wilk BJ, et al. Among authors: van lanschot jjb. J Thorac Dis. 2019 Apr;11(Suppl 5):S621-S631. doi: 10.21037/jtd.2018.11.143. J Thorac Dis. 2019. PMID: 31080638 Free PMC article. Review.
Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer.
van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. van der Wilk BJ, et al. Among authors: van lanschot jjb. Dig Surg. 2019;36(6):462-469. doi: 10.1159/000493435. Epub 2018 Sep 18. Dig Surg. 2019. PMID: 30227434 Free PMC article. Review.
Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommon.
Valkema MJ, Spaander MCW, Boonstra JJ, van Dieren JM, Hazen WL, Erkelens GW, Holster IL, van der Linden A, van der Linde K, Oostenbrug LE, Quispel R, Schoon EJ, Siersema PD, Doukas M, Eyck BM, van der Wilk BJ, van der Sluis PC, Wijnhoven BPL, Lagarde SM, van Lanschot JJB. Valkema MJ, et al. Among authors: van lanschot jjb. Br J Surg. 2023 Sep 6;110(10):1381-1386. doi: 10.1093/bjs/znad211. Br J Surg. 2023. PMID: 37418342 Free PMC article.
128 results